Citius Pharmaceuticals, Inc.: 10-Q filed 2015-02-17
What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2015-02-17 (fiscal Q1 2015): 22 published measures, 46 facts as tagged in accession 0001477932-15-001225.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-02-17
- Fiscal period
- fiscal Q1 2015
- Accession
- 0001477932-15-001225 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 822,638 | USD | |
| At 2014-09-30 | 1,557,461 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -823,546 | USD | |
| At 2014-09-30 | -741,935 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 817,237 | USD | |
| At 2014-09-30 | 1,552,060 | USD | |
| At 2013-12-31 | 54,390 | USD | |
| At 2013-09-30 | 1,272 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -823,708 | USD | 92 |
| 2013-10-01 to 2013-12-31 | -534,414 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -734,823 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -183,164 | USD | 273 |
| 2013-10-01 to 2013-12-31 | -521,882 | USD | 92 |
| 2013-01-01 to 2013-12-31 | -1,095,266 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2013-12-31 | 575,000 | USD | 92 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -6,961,989 | USD | |
| At 2014-09-30 | -6,138,281 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 108,764 | USD | 92 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -878,905 | USD | 92 |
| 2013-10-01 to 2013-12-31 | -499,193 | USD | 92 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 7,500 | USD | 92 |
| 2013-10-01 to 2013-12-31 | 35,221 | USD | 92 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 1,646,184 | USD | |
| At 2014-09-30 | 2,299,396 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 199,076 | USD | |
| At 2014-09-30 | 106,169 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 878,905 | USD | 92 |
| 2013-10-01 to 2013-12-31 | 499,193 | USD | 92 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 477,123 | USD | 92 |
| 2013-10-01 to 2013-12-31 | 437,397 | USD | 92 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 31,080,840 | shares | |
| At 2014-09-30 | 30,025,286 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 6,107,362 | USD | |
| At 2014-09-30 | 5,366,321 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -823,546 | USD | |
| At 2014-09-30 | -741,935 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 520 | USD | |
| At 2014-09-30 | 60,317 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -823,708 | USD | 92 |
| 2013-10-01 to 2013-12-31 | -534,414 | USD | 92 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 293,018 | USD | 92 |
| 2013-10-01 to 2013-12-31 | 61,796 | USD | 92 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 55,197 | USD | 92 |
| 2013-10-01 to 2013-12-31 | -35,221 | USD | 92 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 92,907 | USD | 92 |
| 2013-10-01 to 2013-12-31 | -17,249 | USD | 92 |
Inspect the source
- Entity
- Citius Pharmaceuticals, Inc. / CIK 0001506251
- Captured
- 2026-09-20T09:12:24.553Z
- SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))